Top-News
Advaxis das sieht gut..
Beiträge:
25
Zugriffe: 11.488 / Heute: 2
Zugriffe: 11.488 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +48,05%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +46,01%
SPDR S&P U.S. Consumer Discretionary Select Sector UCITS ETF
Perf. 12M: +42,22%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +41,55%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +41,01%
zu sehn stockcharts.com/h-sc/...=D&b=5&g=0&id=p09870777883
Advaxis to Present at Biotech Showcase™ 2014 in San Francisco
By Business Wire, January 08, 2014, 07:45:00 AM EDTVote upPRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the Company will present at the Biotech Showcase™ 2014 Conference being held at the Parc 55 Wyndham San Francisco Union Square Hotel in San Francisco, CA.Read more: www.nasdaq.com/press-release/...o-20140108-00168#ixzz2qGsM7AmT
By Business Wire, January 08, 2014, 07:45:00 AM EDTVote upPRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the Company will present at the Biotech Showcase™ 2014 Conference being held at the Parc 55 Wyndham San Francisco Union Square Hotel in San Francisco, CA.Read more: www.nasdaq.com/press-release/...o-20140108-00168#ixzz2qGsM7AmT
Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study
By Business Wire, January 21, 2014, 07:30:00 AM ED
Read more: www.nasdaq.com/press-release/...y-20140121-00243#ixzz2r2ICUw4g
By Business Wire, January 21, 2014, 07:30:00 AM ED
Read more: www.nasdaq.com/press-release/...y-20140121-00243#ixzz2r2ICUw4g
...nach dem gestern nachbörslich gemeldeten Pet-Deal...
die Vorbörse wird ja schonmal den Weg zeigen:)
die Vorbörse wird ja schonmal den Weg zeigen:)
...noch kleine Company...ausserdem zeigt es das Potential für weitere
License Verträge:
KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.
Under the agreement, Aratana made a one-time upfront payment to Advaxis of $1 million and an additional $1.5 million equity investment in Advaxis common stock and warrants. Aratana agreed to pay up to an additional $6 million in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs in both United States and the European Union. In addition, Aratana agreed to pay up to $28.5 million in commercial milestones. Upon regulatory approval and commercialization of the immunotherapies, Aratana agreed to pay Advaxis a tiered royalty ranging from mid-single digit to 10% on net sales.
License Verträge:
KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.
Under the agreement, Aratana made a one-time upfront payment to Advaxis of $1 million and an additional $1.5 million equity investment in Advaxis common stock and warrants. Aratana agreed to pay up to an additional $6 million in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs in both United States and the European Union. In addition, Aratana agreed to pay up to $28.5 million in commercial milestones. Upon regulatory approval and commercialization of the immunotherapies, Aratana agreed to pay Advaxis a tiered royalty ranging from mid-single digit to 10% on net sales.
...+ Royalties on net sales!
bei einer Marketcap. von 68 mio.$ von Advaxis ist das schon eine Hausnummer!
bei einer Marketcap. von 68 mio.$ von Advaxis ist das schon eine Hausnummer!
...Aktie, welche bei so einer Meldung ins Minus rutscht stinkt zum Himmel..
ob geshortet, manipuliert oder kein Interesse ist mir wurscht...
ob geshortet, manipuliert oder kein Interesse ist mir wurscht...
Gut gemacht. Der jetzige Preis lädt aber zum Wiedereinstieg ein. biotech
www.globenewswire.com/news-release/2014/12/...-for-Prosta.html
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Ayala Pharmaceuticals Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 75 | Advaxis - Übernahme voraus? | biotech1x1 | Vassago | 23.12.21 15:30 | ||
2 | 24 | Advaxis das sieht gut.. | Bäcker33 | fbo|228862719 | 25.04.21 01:54 |
